Bodybuilding Supplement Awards 2010
Reports from MSLP, NTRI, and OREX
crwefinancelogo2
signup3m
MusclePharm Corporation(OTCBB:MSLP), One of the fastest growing nutritional supplement companies in the United States recently reported a distribution agreement with Sportika Export Inc., a leading sports nutrition distributor, to over 130 countries internationally.
We are very excited about the opportunity to expand distribution into over 130 markets as we continue to grow MusclePharm’s international brand presence, said Brad Pyatt, MusclePharm’s Chief Executive Officer. Creating a strategic partnership with Sportika Export will allow us to broaden our nutritional product formulations availability in the global healthy living and wellness industry as we strive to increase sales and profitability long-term.
MusclePharm’s multiple products are currently available in 1,200 of the top GNC stores in the United States, as well as over 450 Vitamin Shoppe stores. MusclePharm’s award-winning products Assault, Battle Fuel, Bullet Proof, Combat Powder, Recon and Shred Matrixare also available online at gnc.com, bodybuilding.com, amazon.com and many other locations.
It’s been years since Sportika Export has seen the level of interest from distributors abroad that MusclePharm has generated. We’re excited to be part of their huge growth potential and bring it to the 130 plus countries we deal with, commented Richard White, Jr., Sportika’s President. We feel that MusclePharm is the next BIG thing in the Sports Nutrition Industry. Their innovation with products and marketing is going to take them to the top. We look forward to a long lasting successful relationship with MusclePharm.
MusclePharm will begin to distribute products with Sportika Export in September of 2010.
MSLP is a fast-growing developer and manufacturer of safe, scientifically approved nutritional supplements that are free of banned substances and tested by athletes. They are designed to help athletes, bodybuilders, weightlifters and fitness enthusiasts improve their performance. Each and every MusclePharm product is the end result of an advanced six-stage research and testing protocol involving the expertise of top nutrition scientists.
Orexigen Therapeutics, Inc. (Nasdaq:OREX) recently reported that the online publication of results from its COR-BMOD trial of Contrave (naltrexone SR/bupropion SR) in the journal Obesity. The COR-BMOD trial evaluated intensive behavior modification (BMOD) plus Contrave32 (32mg naltrexone sustained release (SR)/360mg bupropion SR) compared to BMOD plus placebo, in 793 overweight or obese patients. The addition of Contrave to BMOD delivered significant incremental weight loss and improvements in measures of cardiometabolic risk. Results showed that patients taking Contrave lost 9.3% of their body weight compared to 5.1% for patients on placebo (p< 0.001), on an intent-to-treat basis. For those who completed 56 weeks of treatment, patients taking Contrave plus BMOD lost 11.5% of their body weight compared to 7.3% for those taking placebo (p<0.001).
OREX is a biopharmaceutical company focused on the treatment of obesity. Our lead combination product candidates targeted for obesity are Contrave (naltrexone SR/bupropion SR), which has completed Phase 3 clinical trials and has submitted an NDA for FDA review, and Empatic (zonisamide SR/bupropion SR), which has completed Phase 2 clinical development.
http://crwefinance.com/img/crwefinance_new_buscard2.jpg
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has received twenty five thousand dollars in cash and seventy five thousand free trading shares from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp. (MSLP.OB).
About the Author
Jul 27 2010 – VID00054.AVI